HC Wainwright Brokers Increase Earnings Estimates for CAPR

Capricor Therapeutics Inc (NASDAQ:CAPR) – HC Wainwright increased their FY2024 EPS estimates for shares of Capricor Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of ($1.33) for the year, up from their previous forecast of ($1.38). HC Wainwright has a “Buy” rating and a $77.00 price objective on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q4 2024 earnings at ($0.30) EPS, FY2025 earnings at ($1.14) EPS and FY2026 earnings at ($0.11) EPS.

A number of other equities analysts also recently commented on the company. Maxim Group boosted their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Oppenheimer reiterated an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. Cantor Fitzgerald lifted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Piper Sandler began coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Price Performance

CAPR opened at $18.61 on Monday. The stock has a market capitalization of $845.01 million, a price-to-earnings ratio of -17.56 and a beta of 4.00. The business has a fifty day moving average price of $15.21 and a 200 day moving average price of $8.50. Capricor Therapeutics has a 12 month low of $2.87 and a 12 month high of $23.40.

Insider Buying and Selling at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of Capricor Therapeutics stock in a transaction on Friday, September 20th. The stock was bought at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This represents a 65.21 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 12.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics during the 1st quarter worth $40,000. Vanguard Group Inc. raised its stake in Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Capricor Therapeutics in the second quarter valued at approximately $147,000. Finally, Main Street Financial Solutions LLC raised its stake in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.